Dutch-American Not-For-Profit Group Joins Roche Pharmaceutical Company to Implement HIV/AIDS Drug Pilot Program in Africa
PharmAccess International, a Dutch-American not-for-profit organization, yesterday announced that it will begin a pilot program in Africa "aimed at widening access" to HIV drugs, Dow Jones International News reports. Swiss pharmaceutical company Roche Holding AG is set to provide funding for the program as well as diagnostic monitoring tests, "technical support for training health care professionals" and HIV/AIDS drugs, including its protease inhibitor Fortovase. PharmAccess "hopes" that the two-year pilot program, which will be implemented in four urban centers in the Ivory Coast, Kenya, Senegal and Uganda, will increase access to HIV/AIDS drugs through HIV/AIDS education and "the build-up of local medical infrastructures" (Dow Jones International News, 1/14).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
